Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tornier to acquire Nexia Orthopedics:

This article was originally published in Clinica

Executive Summary

Orthopaedic extremity device developer Tornier has agreed to acquire Nexa Orthopedics, a fellow specialist in extremities. Nexa is based in San Diego, California, and was founded by HealthpointCapital in 2004. Financial terms of the acquisition were not disclosed. Tornier notes that the deal will expand its technology base with new implantable device materials and coatings as well as enlarging its portfolio of products for surgeons performing procedures on shoulders, arms, hands, feet and ankles. Tornier's US business in Eden Prairie, Minnesota, is part of a family business based in Grenoble, France. In July 2006, Warburg Pincus acquired a majority stake in the company, and Douglas Kohrs, former president and CEO of American Medical Systems, was installed as president and CEO of Tornier, replacing Alain Tornier, who became chairman.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT047603

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel